FTC Under Trump Likely to Maintain PBM Focus But M&A Oversight May Moderate

 
• By Cathy Kelly
  
Attention is Turning To the Incoming Trump Administration. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Legal & IP